All updated as on -
By 2030, the global market for nasopharyngeal carcinoma is estimated to be worth millions of dollars, growing at a CAGR of 5.7% from 2022 to 2030. Nasopharyngeal cancer is expected to grow at a rapid rate over the next several years as the number of people diagnosed with the disease rises. Rarely treated is cancer of the nasopharynx, or nasopharyngeal carcinoma. The nasopharynx is situated between the floor of the mouth and the roof of the skull. Nasopharyngeal cancer symptoms include a sore throat, a lump in the nose or neck, breathing or speaking difficulties, hearing loss, ear pain or ringing, or headaches. Squamous cells lining the nasopharynx are the germinal tissue for nasopharyngeal cancer. Various diagnostic procedures, including the Epstein-Barr virus (EBV) antibody test, X-ray, ultrasound, endoscopy, biopsy, CT scan, MRI, PET scan, or PET-CT scan, can be used to identify nasopharyngeal cancer.
According to the most recent statistics from the World Cancer Research Fund International (WCRF), nasopharyngeal carcinoma will be the 22nd most prevalent cancer in the world in 2022, and the 18th most common cancer among men. In 2020, the WCRF predicts that healthcare providers around the world will evaluate roughly 145,120 new cases of NPC. The National Centre for Biotechnology Information reports that 81 percent of new instances of nasopharyngeal carcinoma are seen in Asia, 8 percent in Africa, and 10 percent in the rest of the world.
Report Coverage
Global Nasopharyngeal Carcinoma research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Nasopharyngeal Carcinoma report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Nasopharyngeal Carcinoma competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Nasopharyngeal Carcinoma market players and analyses their core competencies in each global market sub-segments.
Influential Elements
Increases in both the incidence of nasopharyngeal carcinoma and public understanding of the importance of early detection are likely to fuel the worldwide nasopharyngeal carcinoma market. The ageing population, rising tobacco use, heightened knowledge of health risks, and shifting lifestyles are all factors expected to boost the nasopharyngeal carcinoma therapy market in the coming years. Market growth is forecasted to occur even in the developing world, where healthcare expenditure is rising rapidly and where new technologies are being rapidly adopted in healthcare presumptions. Increasing clinical trials and cancer research efforts present lucrative prospects for future market expansion, but increased government spending on public healthcare presents challenges. The expansion of the nasopharyngeal carcinoma treatment market can also be attributed to the efforts of researchers and healthcare professionals to improve the state of the art in this field.
Limiting Circumstances
High out-of-pocket costs for patients without health insurance to cover their treatment for nasopharyngeal carcinoma due to the high price of curative operations like chemotherapy, surgeries, and radiation therapies. Prescribed for the treatment of nasopharyngeal cancer, the drug's negative effects may also slow the market's expansion.
Analysis of Treatment
Global nasopharyngeal cancer can be broken down into subtypes such as those treated with chemotherapy, immunotherapy, radiation treatment, and others. Chemotherapy, in particular, is expected to grow in popularity during the next few years. The chemotherapy market is expected to expand in the next years as a result of factors such as the increased prevalence of nasopharyngeal cancer and the introduction of new products. According to a study published in the Journal of Clinical Oncology by the American Society of Clinical Oncology (ASCO) in April 2022, combining the chemotherapy drugs gemcitabine (Gemzar) and cisplatin (available as a generic drug) improves survival in patients with advanced nasopharyngeal carcinoma when used in combination with Tislelizumab.
Audience Study
The global nasopharyngeal carcinoma market is segmented by end users into healthcare facilities (hospitals & clinics), ambulatory surgical centres (ASCs), electronics manufacturers (Others), and others. The rapid adoption of technology is anticipated to increase the nasopharyngeal carcinoma market, with hospitals and clinics accounting for the biggest market share over the projection period. The fact that nasopharyngeal carcinoma procedures and therapies are widely accessible in the developed world has also contributed to the market's growth. Market leaders are also pouring resources into developing nations in order to improve healthcare delivery, increase productivity, and better serve patients.
Evaluation of the Area
Due to the presence of significant industry players, which drives technical advances and offers new products, North America is likely to dominate the market throughout the forecast period. The global nasopharyngeal carcinoma market is expected to expand during the projected period on the back of an increase in the number of cases of nasopharyngeal carcinoma and a greater public understanding of the need of early detection and treatment. In addition, an article published in the journal Cancer Medicine in February 2022 noted a dramatic increase in instances of NPC in Mexico during the previous decade. The increasing incidence of carcinoma is driving the expansion of the examined market for treatments for nasopharyngeal cancer.
Revenue-wise, and as a result of rising R&D spending and clinical trials connected with expanding product approval, Asia-Pacific is projected to expand at the fastest CAGR throughout the forecast period. Nasopharyngeal cancer was shown to be more prevalent among the east Asian population.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Nasopharyngeal Carcinoma market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Nasopharyngeal Carcinoma market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Nasopharyngeal Carcinoma market based on the below-mentioned segments:
Global Nasopharyngeal Carcinoma Market, By Type
Global Nasopharyngeal Carcinoma market, By Therapy
Global Nasopharyngeal Carcinoma Market, By End User
Global Nasopharyngeal Carcinoma market, Regional Analysis
According to the most recent statistics from the World Cancer Research Fund International (WCRF), nasopharyngeal carcinoma will be the 22nd most prevalent cancer in the world in 2022, and the 18th most common cancer among men. In 2020, the WCRF predicts that healthcare providers around the world will evaluate roughly 145,120 new cases of NPC. The National Centre for Biotechnology Information reports that 81 percent of new instances of nasopharyngeal carcinoma are seen in Asia, 8 percent in Africa, and 10 percent in the rest of the world.
Report Coverage
Global Nasopharyngeal Carcinoma research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Nasopharyngeal Carcinoma report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Nasopharyngeal Carcinoma competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Nasopharyngeal Carcinoma market players and analyses their core competencies in each global market sub-segments.
Influential Elements
Increases in both the incidence of nasopharyngeal carcinoma and public understanding of the importance of early detection are likely to fuel the worldwide nasopharyngeal carcinoma market. The ageing population, rising tobacco use, heightened knowledge of health risks, and shifting lifestyles are all factors expected to boost the nasopharyngeal carcinoma therapy market in the coming years. Market growth is forecasted to occur even in the developing world, where healthcare expenditure is rising rapidly and where new technologies are being rapidly adopted in healthcare presumptions. Increasing clinical trials and cancer research efforts present lucrative prospects for future market expansion, but increased government spending on public healthcare presents challenges. The expansion of the nasopharyngeal carcinoma treatment market can also be attributed to the efforts of researchers and healthcare professionals to improve the state of the art in this field.
Limiting Circumstances
High out-of-pocket costs for patients without health insurance to cover their treatment for nasopharyngeal carcinoma due to the high price of curative operations like chemotherapy, surgeries, and radiation therapies. Prescribed for the treatment of nasopharyngeal cancer, the drug's negative effects may also slow the market's expansion.
Analysis of Treatment
Global nasopharyngeal cancer can be broken down into subtypes such as those treated with chemotherapy, immunotherapy, radiation treatment, and others. Chemotherapy, in particular, is expected to grow in popularity during the next few years. The chemotherapy market is expected to expand in the next years as a result of factors such as the increased prevalence of nasopharyngeal cancer and the introduction of new products. According to a study published in the Journal of Clinical Oncology by the American Society of Clinical Oncology (ASCO) in April 2022, combining the chemotherapy drugs gemcitabine (Gemzar) and cisplatin (available as a generic drug) improves survival in patients with advanced nasopharyngeal carcinoma when used in combination with Tislelizumab.
Audience Study
The global nasopharyngeal carcinoma market is segmented by end users into healthcare facilities (hospitals & clinics), ambulatory surgical centres (ASCs), electronics manufacturers (Others), and others. The rapid adoption of technology is anticipated to increase the nasopharyngeal carcinoma market, with hospitals and clinics accounting for the biggest market share over the projection period. The fact that nasopharyngeal carcinoma procedures and therapies are widely accessible in the developed world has also contributed to the market's growth. Market leaders are also pouring resources into developing nations in order to improve healthcare delivery, increase productivity, and better serve patients.
Evaluation of the Area
Due to the presence of significant industry players, which drives technical advances and offers new products, North America is likely to dominate the market throughout the forecast period. The global nasopharyngeal carcinoma market is expected to expand during the projected period on the back of an increase in the number of cases of nasopharyngeal carcinoma and a greater public understanding of the need of early detection and treatment. In addition, an article published in the journal Cancer Medicine in February 2022 noted a dramatic increase in instances of NPC in Mexico during the previous decade. The increasing incidence of carcinoma is driving the expansion of the examined market for treatments for nasopharyngeal cancer.
Revenue-wise, and as a result of rising R&D spending and clinical trials connected with expanding product approval, Asia-Pacific is projected to expand at the fastest CAGR throughout the forecast period. Nasopharyngeal cancer was shown to be more prevalent among the east Asian population.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2020 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2019 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Cyclacel Pharmaceuticals, F. Hoffman La-Roche Ltd., Biocon Limited, Bristol Myers Squibb Company, Merck & Co., Inc., Novartis AG, Pfizer, Inc., GlaxoSmithKline (GSK) PLC, Sanofi, Theravectys SA, Eli Lilly And Company, Roche, BioDiem |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Nasopharyngeal Carcinoma Market from 2021 to 2030.
- Market Forecast for Nasopharyngeal Carcinoma Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Nasopharyngeal Carcinoma competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Nasopharyngeal Carcinoma
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Nasopharyngeal Carcinoma market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Nasopharyngeal Carcinoma market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
- Biocon Limited
- Bristol Myers Squibb Company
- Cyclacel Pharmaceuticals
- F. Hoffman La-Roche Ltd.
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- GlaxoSmithKline (GSK) PLC
- Sanofi
- Theravectys SA
- Eli Lilly And Company
- Roche
- BioDiem
Primary Target Market
- Market Players of Nasopharyngeal Carcinoma
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Nasopharyngeal Carcinoma market based on the below-mentioned segments:
Global Nasopharyngeal Carcinoma Market, By Type
- Non-keratinizing undifferentiated carcinoma
- Non-keratinizing differentiated carcinoma
- Keratinizing squamous cell carcinoma
Global Nasopharyngeal Carcinoma market, By Therapy
- Chemotherapy
- Immunotherapy
- Radiation therapy
- Other therapy
Global Nasopharyngeal Carcinoma Market, By End User
- Hospitals & clinics
- Ambulatory surgery Centers
- Cancer Treatment & Rehabilitation Centers
- Others
Global Nasopharyngeal Carcinoma market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive nasopharyngeal carcinoma market market research and competitor analysis for your business to help you develop more profound insights into the nasopharyngeal carcinoma market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the nasopharyngeal carcinoma market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.